Steven L. Basta
CIK: 0001417397
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (13 total)
- Feb 10, 2026PHAT
Phathom Pharmaceuticals, Inc.
Award(A)Direct12.4K shares- - Feb 10, 2026PHAT
Phathom Pharmaceuticals, Inc.
Tax Payment(F)Direct6.3K shares at avg. $12.82$80K - Jan 2, 2026PHAT
Phathom Pharmaceuticals, Inc.
Award(A)Direct251K shares- - Dec 17, 2025PHAT
Phathom Pharmaceuticals, Inc.
Award(A)Direct62K shares- - Dec 17, 2025PHAT
Phathom Pharmaceuticals, Inc.
Tax Payment(F)Direct31.5K shares at avg. $15.36$484K - Dec 12, 2025VYNE
VYNE Therapeutics Inc.
Award(A)DirectStock Option (right to buy)
20K shares- - Nov 28, 2025PHAT
Phathom Pharmaceuticals, Inc.
Tax Payment(F)Direct48.4K shares at avg. $15.62$756K - Nov 28, 2025PHAT
Phathom Pharmaceuticals, Inc.
Exercise(M)Direct90K shares- - Sep 25, 2025PHAT
Phathom Pharmaceuticals, Inc.
Exercise(M)Direct90K shares- - Sep 25, 2025PHAT
Phathom Pharmaceuticals, Inc.
Tax Payment(F)Direct48.4K shares at avg. $11.66$564K - Apr 3, 2025PHAT
Phathom Pharmaceuticals, Inc.
Award(A)DirectPerformance Shares
360K shares- - Apr 3, 2025PHAT
Phathom Pharmaceuticals, Inc.
Award(A)DirectStock Option (Right to Buy)
1.1M shares- - Dec 12, 2024VYNE
VYNE Therapeutics Inc.
Award(A)DirectStock Option (right to buy)
20K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Feb 10, 2026 |  PHAT Phathom Pharmaceuticals, Inc. | Award(A) | 12,362 | - | $0 | Direct |
| Feb 10, 2026 | PHAT Phathom Pharmaceuticals, Inc. | Tax Payment(F) | 6,277 | $12.82 | $80,471 | Direct |
| Jan 2, 2026 | PHAT Phathom Pharmaceuticals, Inc. | Award(A) | 251,034 | - | $0 | Direct |
| Dec 17, 2025 | PHAT Phathom Pharmaceuticals, Inc. | Award(A) | 62,038 | - | - | Direct |
| Dec 17, 2025 | PHAT Phathom Pharmaceuticals, Inc. | Tax Payment(F) | 31,502 | $15.36 | $483,871 | Direct |
| Dec 12, 2025 |  VYNE VYNE Therapeutics Inc. | Award(A) Stock Option (right to buy) | 20,000 | - | - | Direct |
| Nov 28, 2025 | PHAT Phathom Pharmaceuticals, Inc. | Tax Payment(F) | 48,375 | $15.62 | $755,618 | Direct |
| Nov 28, 2025 | PHAT Phathom Pharmaceuticals, Inc. | Exercise(M) | 90,000 | - | - | Direct |
| Sep 25, 2025 | PHAT Phathom Pharmaceuticals, Inc. | Exercise(M) | 90,000 | - | - | Direct |
| Sep 25, 2025 | PHAT Phathom Pharmaceuticals, Inc. | Tax Payment(F) | 48,375 | $11.66 | $564,053 | Direct |
| Apr 3, 2025 | PHAT Phathom Pharmaceuticals, Inc. | Award(A) Performance Shares | 360,000 | - | - | Direct |
| Apr 3, 2025 | PHAT Phathom Pharmaceuticals, Inc. | Award(A) Stock Option (Right to Buy) | 1,085,000 | - | - | Direct |
| Dec 12, 2024 | VYNE VYNE Therapeutics Inc. | Award(A) Stock Option (right to buy) | 20,000 | - | - | Direct |
1-13 of 13 transactions
About Basta Steven L
Basta Steven L (SEC CIK 0001417397) files insider reports with the SEC as President and CEO of Phathom Pharmaceuticals, Inc. (PHAT) and Director of VYNE Therapeutics Inc. (VYNE).
Signal8 holds 9 ownership filings by Basta Steven L (1 Form 3, 8 Form 4), filed between Dec 13, 2024 and Feb 12, 2026. Those filings report 13 transactions, from Dec 12, 2024 to Feb 10, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Basta Steven L's filings is in FLORHAM PARK.
Recent filings by Basta Steven L
- Feb 10, 2026: Grant or award of PHAT shares (Form 4, code A).
- Feb 10, 2026: Tax withholding of PHAT shares (Form 4, code F).
- Jan 2, 2026: Grant or award of PHAT shares (Form 4, code A).
- Dec 17, 2025: Grant or award of PHAT shares (Form 4, code A).
- Dec 17, 2025: Tax withholding of PHAT shares (Form 4, code F).
Other insiders filing for Phathom Pharmaceuticals, Inc. (PHAT)
- Narula Sanjeev, Chief Financial & Bus. Officer
- Breedlove Robert Charles, Principal Accounting Officer
- Parikh Asit, Director
- Topper James N, Director
- Stenhouse Mark, Director
- FIELDS HEIDI, Director